KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Abbott Laboratories (ABT) Amortization - Intangibles (2016 - 2026)

Abbott Laboratories' Amortization - Intangibles history spans 15 years, with the latest figure at $422.0 million for Q1 2026.

  • On a quarterly basis, Amortization - Intangibles changed 0.48% to $422.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was $1.7 billion, a 7.78% decrease, with the full-year FY2025 number at $1.7 billion, down 10.44% from a year prior.
  • Amortization - Intangibles hit $422.0 million in Q1 2026 for Abbott Laboratories, roughly flat from $422.0 million in the prior quarter.
  • Over the last five years, Amortization - Intangibles for ABT hit a ceiling of $512.0 million in Q1 2022 and a floor of $420.0 million in Q1 2025.
  • Historically, Amortization - Intangibles has averaged $468.3 million across 5 years, with a median of $472.0 million in 2024.
  • Biggest five-year swings in Amortization - Intangibles: grew 0.6% in 2022 and later fell 11.02% in 2025.
  • Tracing ABT's Amortization - Intangibles over 5 years: stood at $496.0 million in 2022, then dropped by 3.02% to $481.0 million in 2023, then decreased by 3.33% to $465.0 million in 2024, then decreased by 9.25% to $422.0 million in 2025, then changed by 0.0% to $422.0 million in 2026.
  • Business Quant data shows Amortization - Intangibles for ABT at $422.0 million in Q1 2026, $422.0 million in Q4 2025, and $420.0 million in Q3 2025.